ArticleHaematologica2009

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.

Jamshid Sorouri Khorashad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.